Astellas Splits Sales Emerging Growth In Russia And China, But A Late Entry To India May Soon Be Rewarded
This article was originally published in The Pink Sheet Daily
Executive Summary
Astellas outlines its growth strategy, offering ways the company plans to overcome the sales loss of U.S. patent expiries for blockbusters Prograf (tacrolimus) and Harnal (tamsulosin).